Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. The aim of our study was to evaluate outcomes and prognostic parameters in patients with intrahepatic cholangiocarcinomas treated with second-line chemotherapy.
Methods: A total of 255 consecutive metastatic intrahepatic cholangiocarcinoma (ICC) patients were retrospectively reviewed and clinicopathologic and survival data were collected.
Results: Fourty-four percent of ICC patients underwent second-line chemotherapy. In particular, younger ICC patients with better ECOG PS status, and with disease control after first-line chemotherapy were those who were treated with second-line treatments. Median progression-free survival in the patients treated with second-line chemotherapy was 3 months. Finally, the patients affected by intrahepatic cholangiocarcinoma with better ECOG PS, with prior surgical resection of the primary tumor, who responded to first-line chemotherapy, and had better progression-free survival with second-line chemotherapy, were associated with better outcomes in multivariate analysis.
Conclusions: Not all patients seem to benefit from second-line chemotherapy. To improve therapeutic decisions, performance status and disease control with first-line chemotherapy should lead to the decision on the usefulness of second-line treatments in advanced ICC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672315 | PMC |
| http://dx.doi.org/10.3390/life13112170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
J Immunother Cancer
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Peltopepimut-S is a therapeutic vaccine, which induces specific expansion of both CD4+helper and CD8+cytotoxic T-cells against human papillomavirus type 16 (HPV16) E6/E7 oncoproteins.
Patients And Methods: In a randomized phase 2 trial, we evaluated the efficacy and safety of peltopepimut-S plus cemiplimab compared with cemiplimab alone as first-line or second-line therapy in recurrent/metastatic HPV16-positive head and neck cancer. The primary efficacy endpoint was the objective response rate (ORR) by an independent review (Response Evaluation Criteria in Solid Tumors version 1.
Effect of Lemborexant-Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single-Center Retrospective Study.
Neuropsychopharmacol Rep
September 2025
Department of Pharmaceutical Sciences, School of Pharmacy at Narita International University of Health and Welfare, Narita, Chiba, Japan.
Benzodiazepine and non-benzodiazepine hypnotics (Z-drugs) are known risk factors for adverse events, including delirium and falls. Although formularies are intended to promote appropriate prescribing, few comprehensive studies have assessed their clinical impact in the context of sleep medications. This study aimed to evaluate changes in hypnotic prescribing patterns and associated clinical outcomes following the implementation of a sleep medication formulary.
View Article and Find Full Text PDFAssessing the prevalence of antimicrobial resistance among pediatric patients at Kamuzu Central Hospital, Malawi.
J Infect Dev Ctries
August 2025
Division of Epidemiology and Biostatistics, Global Health Department, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Introduction: Severe bacterial infections cause significant disease burden in developing countries, including Malawi. The situation is compounded by the scarcity of resources, inconsistent availability of antibiotics, and increasing antimicrobial resistance (AMR).
Methodology: This was a descriptive retrospective study where we analyzed blood culture results of pediatric patients admitted to Kamuzu Central Hospital (KCH), Lilongwe, Malawi.
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes.
JAMA Netw Open
September 2025
Division of Cardiology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei, Taiwan.
Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.
Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.
Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.
Cerebral Tuberculoma in a Patient With Pre-extensively Drug-Resistant Tuberculosis and AIDS: Diagnostic and Management Challenges.
Cureus
August 2025
Department of Tuberculosis, Yerevan State Medical University After Mkhitar Heratsi, Yerevan, ARM.
Extrapulmonary tuberculosis (TB), particularly when it involves the central nervous system (CNS), remains a significant clinical challenge. Cerebral tuberculoma, though rare, can present with complex symptoms that overlap with other neurological conditions, making timely diagnosis difficult. The condition demands a multidisciplinary approach for accurate diagnosis and effective management, especially in patients with multiple comorbidities.
View Article and Find Full Text PDF